Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × Crizotinib × Thoracic × Clear all

Status

Completed 19 Active not recruiting 15 Unknown 9 Recruiting 6 Terminated 5 Withdrawn 2 Not yet recruiting 1 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1 Thoracic 1 Plasma cell 1

Conditions

Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

ceritinib 2 tazemetostat 1 taletrectinib 1 sotorasib 1 rovalpituzumab tesirine 1 rociletinib 1 pegilodecakin 1 patritumab deruxtecan 1 osimertinib 1 lorlatinib 1 dabrafenib 1 capmatinib 1 brigatinib 1 belagenpumatucel L 1 alectinib 1 Suspensions 1 Powders 1 Paclitaxel 1 Nivolumab 1 Crizotinib 1 BID protein, human 1 AM0010 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02824094 2017-07-21

Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Pfizer

No longer available

Carcinoma, Non-Small-Cell Lung, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡